Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial
/in Dendritic Cells, Glioblastoma, International PublicationsPresence of functional dendritic cells in patients chronically infected with hepatitis C virus
/in Chronic Virus Hepatitis, International PublicationsResults of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2
/in Dendritic Cells, International Publications, Malignant MelanomaIdiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells
/in Dendritic Cells, International Publications, Multiple MyelomaLarge-scale immunomagnetic selection of CD14+ monocytes to generate dendritic cells for cancer immunotherapy: a phase I study
/in Esophageal Carcinoma, International PublicationsHepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses
/in Chronic Virus Hepatitis, International PublicationsEvaluation of pre-existent immunity in patients with primary breast cancer: molecular and cellular assays to quantify antigen-specific T lymphocytes in peripheral blood mononuclear cells
/in Breast Cancer, Dendritic Cells, International PublicationsDendritic cells mediate NK cell help for Th1 and CTL responses: two-signal requirement for the induction of NK cell helper function
/in Dendritic Cells, International PublicationsDendritic cell-based vaccines in breast and gynaecologic cancer
/in Breast Cancer, Cervical Cancer, Dendritic Cells, International Publications, Ovarian Cancer
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer